Evidence map›Paper›PMID 41648221›Full record

ArticlebioRxiv : the preprint server for biology2026

A patient derived xenograft repository capturing clinical and molecular heterogeneity of large B-cell lymphoma.

Haopeng Yang, Kotaro Arita, Kevin Bowman, Dai Chihara, Jared Henderson, Griffin Rost, Estela Rojas, Sydney Parsons, Priya Lakra, Aneela Abedin and 17 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors.

Haopeng YangDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kotaro AritaDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kevin BowmanDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Dai ChiharaDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jared HendersonDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Griffin RostDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Estela RojasDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sydney ParsonsDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Priya LakraDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Aneela AbedinDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sattva S NeelapuDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Paolo StratiDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Loretta J NastoupilDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Luis FayadDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Swaminathan P IyerDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alma RodriguezDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Frederick B HagemeisterDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Luis MalpicaDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hun Ju LeeDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Laura HiltonCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
David W ScottCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
Richard Eric DavisDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christopher R FlowersDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jason R WestinDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Giorgio InghiramiDepartment of Pathology and Laboratory Medicine, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY 10065, USA.
Francisco VegaDepartment of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael R GreenDepartment of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

Project 4 Green-DavisP01CA272295 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Leandro C Cerchietti, CHRISTOPHER R FLOWERS · 2024 to 2026
$9.3M
Project 3: AI Digital Pathology Tools to Address Disparities in Lymphoma Diagnosis and Classification for Underserved CommunitiesU54CA302435 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CHRISTOPHER R FLOWERS · 2025 to 2026
$7.4M
NCI NIH HHS P01 CA272295NCI NIH HHS U54 CA302435
6 · The paper itself

Abstract

Large B-cell lymphomas (LBCLs) are a clinically and molecularly diverse group of malignancies with a rapidly evolving therapeutic landscape that has introduced new areas of clinical need such as post-CD19 chimeric antigen receptor T (CART19) progression. Patient derived xenograft (PDX) models are an important tool for mechanistic studies and preclinical evaluation of new therapies and can be generated from a variety of clinical contexts that capture tumor-intrinsic resistance mechanisms. We therefore undertook a comprehensive effort to generate PDX models that encompass the molecular landscape of LBCLs and include important clinical scenarios for new drug development. Here we describe the first 48 models within this publicly available repository, capturing the transcriptional and genetic subsets of LBCL. These models also include 23 generated from post-CART progression biopsies which reproduce patterns of progression driven by

Identifiers

PMID41648221
PMCPMC12871651

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.